In HNSCC, PD-L1 is overexpressed in about 50–60% of cases; therefore, PD-1/PD-L1 and PD-L2 inhibitors may represent the main class of immunotherapy drugs for this cancer type. Here, PDCD1LG2 is linked to cancer.